A Phase 3 interventional study of Rituximab and Placebo in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 60 sites in 19 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-04-10.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 11 that started in 2007, is one of 27 in phase 3, and was the 21st registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 11 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 60th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 85 in phase 3, and was the 43rd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 3 arm study assessed the efficacy of rituximab (MabThera®/Rituxan®) in the prevention of progression of structural joint damage in participants with active rheumatoid arthritis who had an inadequate clinical response to methotrexate. Participants were randomized to receive rituximab 500 mg intravenously (iv), rituximab 1000 mg iv, or placebo iv on days 1 and 15 every 24 weeks in the main study; all participants received concomitant methotrexate at a stable dose of 12.5-25 mg/week throughout the study. Further courses of rituximab were provided to eligible participants. Structural joint damage was assessed by magnetic resonance imaging (MRI) at baseline and at intervals during the study.
There were 3 phases in the study: A 52 week long main study, a study extension phase, and a 48 week long safety follow-up phase.
The first course of treatment with placebo or rituximab was initiated on Day 1 of the 52 week long main study. A second course of treatment was initiated after Week 24, if the participant met eligibility criteria. After Week 52, eligible participants received further treatment courses at intervals ≥ 6 months in the study extension phase. No treatments were administered in the safety follow-up phase.
Participants had to meet the following eligibility criteria to receive rituximab in the study extension phase.
Patient had not developed contraindications for receiving rituximab, such as:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
Biological: Rituximab · Drug: Methylprednisolone · Drug: Methotrexate · Drug: Folic acid or folate
Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
Biological: Rituximab · Drug: Methylprednisolone · Drug: Methotrexate · Drug: Folic acid or folate
Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
Drug: Placebo · Drug: Methylprednisolone · Drug: Methotrexate · Drug: Folic acid or folate
Rituximab was supplied as a sterile liquid for iv administration.
Also known as: MabThera®, Rituxan®
Placebo was supplied as a sterile liquid in single-use vials for iv administration.
Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24
The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.
Time frame: Baseline to Week 24
Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Weeks 12 and 52
The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.
Time frame: Baseline to Week 52
Change in Magnetic Resonance Imaging (MRI) Synovitis Score From Baseline to Weeks 12, 24, and Week 52
The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 3 wrist regions and 5 metacarpophalangeal joints in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% enhancement of the maximum volume of enhancing tissue in the synovial compartment using the following scale: 0.0=normal, no synovitis; 0.5=1-17% estimated volume of enhancement; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% estimated volume of enhancement. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.
Time frame: Baseline to Week 52
Change in Magnetic Resonance Imaging (MRI) Osteitis Score From Baseline to Weeks 12, 24, and Week 52
The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% increase in the volume of the peripheral 1 cm of original (eroded + residual) articular bone using the following scale: 0.0=normal, no osteitis; 0.5=1-17% involvement of original articular bone; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% involvement of original articular bone. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.
Time frame: Baseline to Week 52
Percentage of Participants With no Newly Eroded Joints at Weeks 24 and 52
No newly eroded joints was defined as no new erosions in joints which were scored 0 at baseline. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion.
Time frame: Baseline to Week 52
Percentage of Participants With no Progression/no Worsening in Bone Erosion at Weeks 24 and 52
There were 2 definitions of no progression/no worsening in bone erosion. A participant met the criterion for definition 1 when there was a change in the magnetic resonance imaging erosion score ≤ 0. A participant met the criteria for definition 2 when there was either (1) no change from Baseline in the MRI erosion score, (2) an increase in erosion score and the size of the increase in score was smaller than the smallest detectable change, or (3) a drop in the erosion score. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.
Time frame: Baseline to Week 52
Percentage of Participants With Improvement in Synovitis at Weeks 24 and 52
There were 2 definitions of improvement in synovitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> than the smallest detectable change. The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.
Time frame: Baseline to Week 52
Percentage of Participants With Improvement in Osteitis at Weeks 24 and 52
There were 2 definitions of improvement in osteitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> than the smallest detectable change. The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.
Time frame: Baseline to Week 52
Change From Baseline in the Disease Activity Score 28 (DAS28) at Weeks 24 and 52
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, C-reactive protein level (CRP), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
Time frame: Baseline to Week 52
Percentage of Participants With European League Against Rheumatism (EULAR) Good, Moderate, or no Response at Weeks 24 and 52
Change of the DAS28 score from Baseline was used to determine the EULAR responses. For a post-Baseline score ≤ 3.2, a change from Baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-Baseline score \> 3.2 to ≤ 5.1, a change from Baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-Baseline score \> 5.1, a change from Baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-Baseline scores \> 3.2. DAS28=(0.56×√(TJC28))+(0.28×√(SJC28))+(0.7×log(CRP))+(0.014×GH), where TJC28=tender joint count (JC) and SJC28=swollen JC (28 joints), GH=a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end=no disease activity, right end=maximum disease activity), and CRP=C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Baseline to Week 52
Percentage of Participants With Low Disease Activity (Disease Activity Score 28 [DAS28] ≤ 3.2) at Weeks 24 and 52
The percentage of participants who had low rheumatic arthritis disease activity at Weeks 24 and 52, as measured by a DAS28 score ≤ 3.2, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Baseline to Week 52
Percentage of Participants in Remission Response (Disease Activity Score 28 [DAS28] < 2.6) at Weeks 24 and 52
The percentage of participants in remission of their rheumatic arthritis at Weeks 24 and 52, as measured by a DAS28 score \< 2.6, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Baseline to Week 52
Percentage of Participants With an Improvement of at Least 20%, 50%, or 70% in the American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline at Weeks 24 and 52
Improvement must be seen in tender and swollen joint counts (28 assessed joints; Joints were evaluated and classified as swollen or not swollen and tender or not tender based on pressure and joint manipulation upon physical examination) and in at least 3
Time frame: Baseline to Week 52
Percentage of Participants Achieving a Major Clinical Response at Week 52
A major clinical response was defined as an improvement of at least 70% in the American College of Rheumatology score from Baseline at Week 52. Improvement must be seen in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate participant and physician assessments of participant disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"); participant assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein level.
Time frame: Baseline to Week 52
Correlation of Magnetic Resonance Imaging Assessments and Clinical Outcome Measures
Correlation coefficients of magnetic resonance imaging erosion, synovitis, and osteitis scores and clinical outcome measures of swollen joint count (SJC), tender joint count (TJC), C-reactive protein level (CRP), erythrocyte sedimentation rate (ESR), a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (GH), Disease Activity Score 28-C-reactive protein (DAS28-CRP), and Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) are reported. Not all of these variables were specified as primary or secondary Outcome Measures in the study protocol and were not individually analyzed.
Time frame: Baseline to Week 52
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 24 and 52
The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Time frame: Baseline to Week 52
Adverse Events (AEs), Laboratory Parameters, C-reactive Protein, ESR.
Time frame: Throughout study
| Milestone | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Started | 62 | 60 | 63 |
| Treated | 62 | 60 | 63 |
| Completed | 59 | 56 | 49 |
| Not completed | 3 | 4 | 14 |
| Milestone | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Started | 53 | 50 | 43 |
| Completed | 49 | 49 | 40 |
| Not completed | 4 | 1 | 3 |
| Milestone | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Started | 57 | 54 | 54 |
| Completed | 11 | 9 | 8 |
| Not completed | 46 | 45 | 46 |
The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.
| Units on a scale | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24 | 0.13 ± 2.258 | 0.39 ± 1.807 | 1.33 ± 2.235 |
The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.
| Units on a scale | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 12 (n = 58, 58, 56) | 0.42 ± 1.693 | 0.13 ± 1.764 | 0.33 ± 4.122 |
| Week 52 (n = 56, 57, 58) | 0.11 ± 2.623 | -0.30 ± 2.372 | 3.02 ± 4.456 |
The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 3 wrist regions and 5 metacarpophalangeal joints in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% enhancement of the maximum volume of enhancing tissue in the synovial compartment using the following scale: 0.0=normal, no synovitis; 0.5=1-17% estimated volume of enhancement; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% estimated volume of enhancement. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.
| Units on a scale | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 12 (n = 58, 58, 56) | -0.50 ± 1.701 | -1.15 ± 1.866 | -0.22 ± 2.050 |
| Week 24 (n = 61, 59, 59) | -1.14 ± 1.923 | -1.81 ± 2.289 | 0.20 ± 2.257 |
| Week 52 (n = 61, 59, 59) | -2.03 ± 2.562 | -2.73 ± 3.120 | -0.01 ± 2.700 |
The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% increase in the volume of the peripheral 1 cm of original (eroded + residual) articular bone using the following scale: 0.0=normal, no osteitis; 0.5=1-17% involvement of original articular bone; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% involvement of original articular bone. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.
| Units on a scale | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 12 (n = 58, 58, 56) | -2.11 ± 5.049 | -1.88 ± 5.366 | -0.14 ± 3.940 |
| Week 24 (n = 61, 59, 59) | -2.91 ± 5.687 | -2.86 ± 5.976 | 0.07 ± 5.574 |
| Week 52 (n = 61, 59, 59) | -4.75 ± 7.413 | -3.83 ± 6.255 | -0.22 ± 6.390 |
No newly eroded joints was defined as no new erosions in joints which were scored 0 at baseline. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 | 77.4 | 73.3 | 55.5 |
| Week 52 | 77.4 | 40 | 60.3 |
There were 2 definitions of no progression/no worsening in bone erosion. A participant met the criterion for definition 1 when there was a change in the magnetic resonance imaging erosion score ≤ 0. A participant met the criteria for definition 2 when there was either (1) no change from Baseline in the MRI erosion score, (2) an increase in erosion score and the size of the increase in score was smaller than the smallest detectable change, or (3) a drop in the erosion score. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 (Definition 1) | 50.0 | 51.7 | 33.3 |
| Week 24 (Definition 2) | 88.7 | 96.7 | 81.0 |
| Week 52 (Definition 1) | 48.4 | 55.0 | 27.0 |
| Week 52 (Definition 2) | 85.5 | 93.3 | 55.6 |
There were 2 definitions of improvement in synovitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> than the smallest detectable change. The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 (Definition 1) | 41.9 | 56.7 | 22.2 |
| Week 24 (Definition 2) | 41.9 | 56.7 | 22.2 |
| Week 52 (Definition 1) | 54.8 | 60.0 | 25.4 |
| Week 52 (Definition 2) | 54.8 | 60.0 | 25.4 |
There were 2 definitions of improvement in osteitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> than the smallest detectable change. The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 (Definition 1) | 50.0 | 51.7 | 22.2 |
| Week 24 (Definition 2) | 50.0 | 51.7 | 22.2 |
| Week 52 (Definition 1) | 58.1 | 51.7 | 27.0 |
| Week 52 (Definition 2) | 58.1 | 51.7 | 27.0 |
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, C-reactive protein level (CRP), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
| Units on a scale | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 (n = 63, 62, 59) | -1.714 ± 1.2204 | -1.683 ± 1.0158 | -0.752 ± 1.1834 |
| Week 52 (n = 63, 62, 59) | -2.055 ± 1.1844 | -1.801 ± 1.0443 | -0.747 ± 1.2557 |
Change of the DAS28 score from Baseline was used to determine the EULAR responses. For a post-Baseline score ≤ 3.2, a change from Baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-Baseline score \> 3.2 to ≤ 5.1, a change from Baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-Baseline score \> 5.1, a change from Baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-Baseline scores \> 3.2. DAS28=(0.56×√(TJC28))+(0.28×√(SJC28))+(0.7×log(CRP))+(0.014×GH), where TJC28=tender joint count (JC) and SJC28=swollen JC (28 joints), GH=a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end=no disease activity, right end=maximum disease activity), and CRP=C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 - No response | 33.9 | 22.0 | 58.7 |
| Week 24 - Moderate response | 37.1 | 42.4 | 22.2 |
| Week 24 - Good response | 29.0 | 35.6 | 19.0 |
| Week 52 (n = 63, 62, 59) - No response | 21.0 | 13.6 | 60.3 |
| Week 52 (n = 63, 62, 59) - Moderate response | 45.2 | 49.2 | 31.7 |
| Week 52 (n = 63, 62, 59) - Good response | 33.9 | 37.3 | 7.9 |
The percentage of participants who had low rheumatic arthritis disease activity at Weeks 24 and 52, as measured by a DAS28 score ≤ 3.2, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 | 33.9 | 36.7 | 19.0 |
| Week 52 | 37.1 | 38.3 | 9.5 |
The percentage of participants in remission of their rheumatic arthritis at Weeks 24 and 52, as measured by a DAS28 score \< 2.6, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 | 21.0 | 28.3 | 12.7 |
| Week 52 | 25.8 | 25.0 | 7.9 |
Improvement must be seen in tender and swollen joint counts (28 assessed joints; Joints were evaluated and classified as swollen or not swollen and tender or not tender based on pressure and joint manipulation upon physical examination) and in at least 3
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 - ACR20 response | 51.6 | 51.7 | 28.6 |
| Week 24 - ACR50 response | 24.2 | 26.7 | 11.1 |
| Week 24 - ACR70 response | 11.3 | 8.3 | 1.6 |
| Week 52 - ACR20 response | 67.7 | 68.3 | 28.6 |
| Week 52 - ACR50 response | 37.1 | 35.0 | 14.3 |
| Week 52 - ACR70 response | 17.7 | 16.7 | 6.3 |
A major clinical response was defined as an improvement of at least 70% in the American College of Rheumatology score from Baseline at Week 52. Improvement must be seen in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate participant and physician assessments of participant disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"); participant assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein level.
| Percentage of participants | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving a Major Clinical Response at Week 52 | 6.5 | 6.7 | 1.6 |
Correlation coefficients of magnetic resonance imaging erosion, synovitis, and osteitis scores and clinical outcome measures of swollen joint count (SJC), tender joint count (TJC), C-reactive protein level (CRP), erythrocyte sedimentation rate (ESR), a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (GH), Disease Activity Score 28-C-reactive protein (DAS28-CRP), and Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) are reported. Not all of these variables were specified as primary or secondary Outcome Measures in the study protocol and were not individually analyzed.
| Correlation coefficient | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Erosion score and SJC - Week 24 | 0.341 | 0.425 | 0.446 |
| Erosion score and SJC - Week 52 | 0.287 | 0.234 | 0.355 |
| Synovitis score and SJC - Week 24 | 0.329 | 0.389 | 0.566 |
| Synovitis score and SJC - Week 52 | 0.168 | 0.188 | 0.574 |
| Osteitis score and SJC - Week 24 | 0.407 | 0.354 | 0.370 |
| Osteitis score and SJC - Week 52 | 0.265 | 0.192 | 0.398 |
| Erosion score and TJC - Week 24 | 0.364 | 0.115 | 0.298 |
| Erosion score and TJC - Week 52 | 0.275 | 0.067 | 0.425 |
| Synovitis score and TJC - Week 24 | 0.336 | 0.174 | 0.282 |
| Synovitis score and TJC - Week 52 | 0.142 | 0.036 | 0.421 |
| Osteitis score and TJC - Week 24 | 0.355 | 0.118 | 0.288 |
| Osteitis score and TJC - Week 52 | 0.245 | 0.048 | 0.371 |
| Erosion score and CRP - Week 24 | 0.185 | -0.024 | 0.006 |
| Erosion score and CRP - Week 52 | 0.055 | 0.098 | 0.352 |
| Synovitis score and CRP - Week 24 | 0.030 | 0.090 | 0.192 |
| Synovitis score and CRP - Week 52 | -0.077 | 0.085 | 0.311 |
| Osteitis score and CRP - Week 24 | -0.031 | -0.057 | 0.040 |
| Osteitis score and CRP - Week 52 | 0.005 | -0.010 | 0.119 |
| Erosion score and ESR - Week 24 | 0.321 | 0.136 | 0.197 |
| Erosion score and ESR - Week 52 | 0.127 | 0.188 | 0.314 |
| Synovitis score and ESR - Week 24 | 0.182 | 0.214 | 0.358 |
| Synovitis score and ESR - Week 52 | 0.185 | 0.248 | 0.360 |
| Osteitis score and ESR - Week 24 | 0.044 | 0.043 | 0.148 |
| Osteitis score and ESR - Week 52 | -0.041 | 0.116 | 0.205 |
| Erosion score and GH - Week 24 | 0.206 | 0.043 | 0.326 |
| Erosion score and GH - Week 52 | 0.063 | -0.009 | 0.316 |
| Synovitis score and GH - Week 24 | 0.186 | 0.221 | 0.206 |
| Synovitis score and GH - Week 52 | -0.026 | -0.037 | 0.286 |
| Osteitis score and GH - Week 24 | 0.274 | 0.122 | 0.205 |
| Osteitis score and GH - Week 52 | 0.106 | 0.052 | 0.136 |
| Erosion score and DAS28-CRP - Week 24 | 0.420 | 0.198 | 0.457 |
| Erosion score and DAS28-CRP - Week 52 | 0.238 | 0.127 | 0.498 |
| Synovitis score and DAS28-CRP - Week 24 | 0.393 | 0.349 | 0.437 |
| Synovitis score and DAS28-CRP - Week 52 | 0.149 | 0.150 | 0.500 |
| Osteitis score and DAS28-CRP - Week 24 | 0.380 | 0.209 | 0.351 |
| Osteitis score and DAS28-CRP - Week 52 | 0.139 | 0.143 | 0.356 |
| Erosion score and DAS28-ESR - Week 24 | 0.429 | 0.255 | 0.439 |
| Erosion score and DAS28-ESR - Week 52 | 0.244 | 0.180 | 0.473 |
| Synovitis score and DAS28-ESR - Week 24 | 0.398 | 0.332 | 0.438 |
| Synovitis score and DAS28-ESR - Week 52 | 0.198 | 0.147 | 0.514 |
| Osteitis score and DAS28-ESR - Week 24 | 0.353 | 0.231 | 0.353 |
| Osteitis score and DAS28-ESR - Week 52 | 0.108 | 0.172 | 0.356 |
The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
| Units on a scale | Rituximab 500 mg | Rituximab 1000 mg | Placebo |
|---|---|---|---|
| Week 24 (n = 63, 62, 59) | -0.425 ± 0.5606 | -0.439 ± 0.4770 | -0.194 ± 0.5849 |
| Week 52 (n = 63, 62, 59) | -0.520 ± 0.5873 | -0.417 ± 0.4450 | -0.177 ± 0.5943 |
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab 500 mg - Double-blind Treatment Phase | — | 3/62 (4.8%) | 24/62 (38.7%) |
| Rituximab 1000 mg - Double-blind Treatment Phase | — | 4/60 (6.7%) | 24/60 (40%) |
| Placebo - Double-blind Treatment Phase | — | 5/63 (7.9%) | 20/63 (31.7%) |
| Rituximab 500 mg - Extension Phase | — | 3/50 (6%) | 0/50 (0%) |
| Rituximab 1000 mg - Extension Phase | — | 5/47 (10.6%) | 0/47 (0%) |
| Placebo - Extension Phase | — | 2/41 (4.9%) | 0/41 (0%) |
| Rituximab 500 mg - Safety Follow-up Phase | — | 0/57 (0%) | 0/57 (0%) |
| Rituximab 1000 mg - Safety Follow-up Phase | — | 1/54 (1.9%) | 0/54 (0%) |
| Placebo - Safety Follow-up Phase | — | 0/54 (0%) | 0/54 (0%) |
| Event | Rituximab 500 mg - Double-blind Treatment Phase | Rituximab 1000 mg - Double-blind Treatment Phase | Placebo - Double-blind Treatment Phase | Rituximab 500 mg - Extension Phase | Rituximab 1000 mg - Extension Phase | Placebo - Extension Phase | Rituximab 500 mg - Safety Follow-up Phase | Rituximab 1000 mg - Safety Follow-up Phase | Placebo - Safety Follow-up Phase |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/62 | 0/60 | 2/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| ErysipelasInfections and infestations | 0/62 | 0/60 | 0/63 | 0/50 | 0/47 | 1/41 | 0/57 | 0/54 | 0/54 |
| Cholecystitis acuteHepatobiliary disorders | 0/62 | 0/60 | 0/63 | 0/50 | 0/47 | 1/41 | 0/57 | 0/54 | 0/54 |
| CholelithiasisHepatobiliary disorders | 0/62 | 0/60 | 0/63 | 0/50 | 0/47 | 1/41 | 0/57 | 0/54 | 0/54 |
| Respiratory tract infection viralInfections and infestations | 0/62 | 0/60 | 0/63 | 0/50 | 1/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Back painMusculoskeletal and connective tissue disorders | 0/62 | 0/60 | 0/63 | 0/50 | 1/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Knee deformityMusculoskeletal and connective tissue disorders | 0/62 | 0/60 | 0/63 | 0/50 | 1/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/62 | 0/60 | 0/63 | 0/50 | 1/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/62 | 0/60 | 0/63 | 0/50 | 1/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Breast massReproductive system and breast disorders | 0/62 | 0/60 | 0/63 | 0/50 | 1/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Event | Rituximab 500 mg - Double-blind Treatment Phase | Rituximab 1000 mg - Double-blind Treatment Phase | Placebo - Double-blind Treatment Phase | Rituximab 500 mg - Extension Phase | Rituximab 1000 mg - Extension Phase | Placebo - Extension Phase | Rituximab 500 mg - Safety Follow-up Phase | Rituximab 1000 mg - Safety Follow-up Phase | Placebo - Safety Follow-up Phase |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritisImmune system disorders | 2/62 | 1/60 | 6/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| BronchitisInfections and infestations | 4/62 | 5/60 | 2/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Back painMusculoskeletal and connective tissue disorders | 1/62 | 4/60 | 1/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 2/62 | 4/60 | 1/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/62 | 0/60 | 1/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| HeadacheNervous system disorders | 4/62 | 0/60 | 1/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Viral infectionInfections and infestations | 4/62 | 3/60 | 2/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| HypertensionVascular disorders | 0/62 | 1/60 | 4/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 2/62 | 3/60 | 2/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
| Oral herpesInfections and infestations | 1/62 | 3/60 | 0/63 | 0/50 | 0/47 | 0/41 | 0/57 | 0/54 | 0/54 |
Safety population: All participants who received any part of an infusion of the study drug during the main study.
| Age, Continuous(years) | Rituximab 500 mg | Rituximab 1000 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 48.7 ± 11.10 | 50.7 ± 11.65 | 50.3 ± 11.94 | 49.9 ± 11.54 |
| Sex: Female, Male(Participants) | Rituximab 500 mg | Rituximab 1000 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 45 | 50 | 48 | 143 |
| Male | 17 | 10 | 15 | 42 |
The record gives a start of Nov 2007, a primary completion of Nov 2009 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab